BrainStorm Cell Therapeutics, developers of the phase 3 clinical trial candidate NurOwn, announced today that they will not be offering access to that product under “Right to Try” at this time. In a press release today, the company said that they were unable to find a “practical funding solution” to providing access to the treatment candidate under the recent legislation.

"We feel a tremendous sense of urgency and responsibility to provide an ethical, compassionate, and well-reasoned practical response to the demand for NurOwn and have worked tirelessly with patients and other stakeholders to find a solution," said Chaim Lebovits, president and CEO of BrainStorm, "As we were unable to identify a practical funding solution, we unfortunately are not in a position to initiate access to NurOwn under RTT at this time."

The company held a brief conference call shortly after announcing their decision not to offer Right to Try access to NurOwn. In a Reuters article out just before the conference call, Mr. Lebovits said he would personally “sponsor” access to NurOwn under the Right to Try pathway for Matt Bellina, but that at this time his company had made the decision not to offer it to more. He added that he and his company hope to be able to update their Right to Try policy soon, should his company be able to address their funding needs.

NurOwn is the subject of a phase 3 clinical trial in people with ALS that is still actively seeking participants. The trial is currently open for enrollment at six different ALS clinics in the United States. People with ALS interested in learning more about the trial are encouraged to do so online here.

Helpful Links: